PMID- 19501791
OWN - NLM
STAT- MEDLINE
DCOM- 20090727
LR  - 20220321
IS  - 1879-0070 (Electronic)
IS  - 0732-8893 (Linking)
VI  - 64
IP  - 3
DP  - 2009 Jul
TI  - In vitro antibacterial activity of tigecycline against resistant Gram-negative 
      bacilli and enterococci by time-kill assay.
PG  - 300-4
LID - 10.1016/j.diagmicrobio.2009.03.023 [doi]
AB  - This time-kill study was performed with 65 genetically unique clinical isolates 
      of Gram-negative bacilli and enterococci to further define the antibacterial 
      activity of tigecycline. To our knowledge, this is the largest published 
      time-kill study evaluating tigecycline activity to date. Isolates evaluated were 
      10 meropenem-resistant Acinetobacter baumannii; 15 Escherichia coli, including 10 
      extended-spectrum beta-lactamase (ESBL) producers; 15 Klebsiella pneumoniae, 
      including 10 ESBL producers; 20 vancomycin-resistant Enterococcus faecium (VRE), 
      including 10 that were linezolid resistant; and 5 vancomycin-susceptible 
      Enterococcus faecalis. Time-kill testing was performed using tigecycline 
      concentrations of 1x, 2x, and 4x MIC with colony-forming units (CFU) per 
      milliliter determined at 0, 4, 8, 12, 24, 36, and 48 h. Tigecycline MICs 
      (microg/mL) were < or =1 for E. coli and K. pneumoniae, regardless of the 
      isolates' ESBL production; A. baumannii, 0.06 to 4; 9/10 (90%) were < or =2; E. 
      faecalis < or =0.12; and VRE < or =0.25, regardless of linezolid susceptibility. 
      In the time-kill assay, tigecycline significantly inhibited bacterial growth when 
      compared with the growth control. The reduction in growth was <3 log(10) CFU/mL 
      for all isolates, indicative of a bacteriostatic effect.
FAU - Pankey, George A
AU  - Pankey GA
AD  - Infectious Disease Research, Ochsner Clinic Foundation, New Orleans, LA 70121, 
      USA. gpankey@ochsner.org
FAU - Ashcraft, Deborah S
AU  - Ashcraft DS
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Diagn Microbiol Infect Dis
JT  - Diagnostic microbiology and infectious disease
JID - 8305899
RN  - 0 (Anti-Bacterial Agents)
RN  - 70JE2N95KR (Tigecycline)
RN  - FYY3R43WGO (Minocycline)
SB  - IM
MH  - Anti-Bacterial Agents/*pharmacology
MH  - Colony Count, Microbial
MH  - Enterococcus/*drug effects
MH  - Gram-Negative Bacteria/*drug effects
MH  - Humans
MH  - Microbial Sensitivity Tests
MH  - Microbial Viability/*drug effects
MH  - Minocycline/*analogs & derivatives/pharmacology
MH  - Tigecycline
MH  - Time Factors
EDAT- 2009/06/09 09:00
MHDA- 2009/07/28 09:00
CRDT- 2009/06/09 09:00
PHST- 2008/12/05 00:00 [received]
PHST- 2009/03/11 00:00 [revised]
PHST- 2009/03/21 00:00 [accepted]
PHST- 2009/06/09 09:00 [entrez]
PHST- 2009/06/09 09:00 [pubmed]
PHST- 2009/07/28 09:00 [medline]
AID - S0732-8893(09)00130-8 [pii]
AID - 10.1016/j.diagmicrobio.2009.03.023 [doi]
PST - ppublish
SO  - Diagn Microbiol Infect Dis. 2009 Jul;64(3):300-4. doi: 
      10.1016/j.diagmicrobio.2009.03.023.